---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000011"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-01-31T23:59:59+00:00"
generated_at: "2026-06-06T14:28:40.034345+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BSX Q4 sales $3.73B (+14.9% reported), adj EPS $0.55; FY2024 adj EPS guidance $2.23-$2.27

## Summary
- Q4 net sales $3.725B (+14.9% reported); GAAP EPS $0.34, adj EPS $0.55 beat guidance ranges.
- FY2023 net sales $14.240B (+12.3% reported); GAAP EPS $1.07; adj EPS $2.05 versus $1.71 prior year.
- FY2024 guidance: reported sales growth 8.5-9.5%; GAAP EPS $1.38-$1.42; adj EPS $2.23-$2.27.
- FDA approved FARAPULSE PFA System for paroxysmal atrial fibrillation; enrollment in AVANT GUARD trial commenced.
- Agreed to acquire Axonics (AXNX) for urinary/bowel dysfunction treatment; Relievant Medsystems acquisition completed.

## SEC filing metadata
- accession: 0000885725-24-000011
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-01-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/0000885725-24-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/bsx-20240131.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000011
- JSON: https://secwatch.observer/filing/0000885725-24-000011.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000011.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported financial results for the fourth quarter and full year ended December 31, 2023.
  - Period: the fourth quarter and full year ended December 31, 2023
  - Result: reported results
  source text: On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572524000011/0000885725-24-000011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.